News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
178,391 Results
Type
Article (13265)
Company Profile (25)
Press Release (165101)
Section
Business (49810)
Career Advice (619)
Deals (9253)
Drug Delivery (34)
Drug Development (28480)
Employer Resources (70)
FDA (4765)
Job Trends (3926)
News (92894)
Policy (7993)
Tag
2024 BioMidwest Digital (2)
2024 Bio NC Digital (1)
2024 Biotech Bay Standard (5)
2024 Biotech Beach Standard (1)
2024 Genetown Standard (2)
2024 Pharm Country Standard (2)
2026 Pharm Country Premier (1)
2026 Pharm Country Standard (1)
Academia (1083)
Academic (1)
Adcomms (6)
Allergies (29)
Alliances (14114)
ALS (37)
Alzheimer's disease (425)
Antibody-drug conjugate (ADC) (25)
Approvals (4778)
Artificial intelligence (56)
Autoimmune disease (7)
Automation (3)
Bankruptcy (70)
Best Places to Work (3242)
BIOSECURE Act (6)
Biosimilars (48)
Biotechnology (12)
Bladder cancer (19)
Brain cancer (8)
Breast cancer (72)
Cancer (542)
Cardiovascular disease (59)
Career advice (519)
Career pathing (13)
CAR-T (44)
Cell therapy (106)
Cervical cancer (9)
Clinical research (24164)
Collaboration (172)
Compensation (11)
Complete response letters (1)
COVID-19 (1082)
CRISPR (8)
C-suite (54)
Cystic fibrosis (22)
Data (677)
Denatured (6)
Depression (8)
Diabetes (93)
Diagnostics (1709)
Digital health (4)
Diversity (5)
Diversity, equity & inclusion (28)
Drug discovery (34)
Drug pricing (51)
Drug shortages (16)
Duchenne muscular dystrophy (31)
Earnings (14518)
Editorial (15)
Employer branding (5)
Employer resources (64)
Events (21105)
Executive appointments (173)
FDA (5075)
Featured Employer (10)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (191)
Gene editing (17)
Generative AI (7)
Gene therapy (85)
GLP-1 (294)
Government (1193)
Grass and pollen (1)
Guidances (10)
Healthcare (5451)
Huntington's disease (6)
IgA nephropathy (8)
Immunology and inflammation (30)
Indications (6)
Infectious disease (1127)
Inflammatory bowel disease (52)
Inflation Reduction Act (5)
Influenza (14)
Intellectual property (16)
Interviews (106)
IPO (3510)
IRA (26)
Job creations (812)
Job search strategy (458)
Kidney cancer (2)
Labor market (6)
Layoffs (85)
Leadership (6)
Legal (1579)
Liver cancer (21)
Lung cancer (64)
Lymphoma (41)
Machine learning (2)
Management (23)
Manufacturing (62)
MASH (39)
Medical device (3165)
Medtech (3167)
Mergers & acquisitions (5877)
Metabolic disorders (226)
Multiple sclerosis (35)
NASH (19)
Neurodegenerative disease (21)
Neuropsychiatric disorders (4)
Neuroscience (593)
NextGen: Class of 2025 (2028)
Non-profit (1647)
Northern California (495)
Obesity (107)
Opinion (53)
Ovarian cancer (16)
Pain (28)
Pancreatic cancer (18)
Parkinson's disease (49)
Partnered (7)
Patents (27)
Patient recruitment (32)
Peanut (17)
People (17692)
Pharmaceutical (12)
Pharmacy benefit managers (12)
Phase I (5380)
Phase II (10361)
Phase III (9823)
Pipeline (276)
Podcasts (12)
Policy (52)
Postmarket research (1210)
Preclinical (1933)
Press Release (29)
Prostate cancer (33)
Psychedelics (9)
Radiopharmaceuticals (62)
Rare diseases (102)
Real estate (1405)
Recruiting (23)
Regulatory (5824)
Reports (14)
Research institute (902)
Resumes & cover letters (82)
Rett syndrome (1)
RSV (18)
Schizophrenia (25)
Series A (46)
Series B (30)
Service/supplier (2)
Sickle cell disease (11)
Southern California (468)
Special edition (3)
Spinal muscular atrophy (62)
Sponsored (4)
Startups (1206)
Stomach cancer (4)
Supply chain (13)
The Weekly (6)
United States (4610)
Vaccines (274)
Venture capitalists (8)
Webinars (6)
Weight loss (79)
Women's health (15)
Worklife (6)
Date
Today (48)
Last 7 days (189)
Last 30 days (704)
Last 365 days (8346)
2025 (2040)
2024 (8622)
2023 (9760)
2022 (13255)
2021 (14811)
2020 (14300)
2019 (13759)
2018 (10627)
2017 (9760)
2016 (9356)
2015 (11019)
2014 (7555)
2013 (5950)
2012 (6396)
2011 (6745)
2010 (5808)
Location
Africa (263)
Alabama (8)
Alaska (4)
Arizona (40)
Arkansas (2)
Asia (12604)
Australia (2423)
California (1156)
Canada (362)
China (142)
Colorado (51)
Connecticut (56)
Delaware (33)
Europe (34585)
Florida (159)
Georgia (73)
Idaho (14)
Illinois (140)
India (10)
Indiana (85)
Iowa (2)
Japan (61)
Kansas (29)
Kentucky (7)
Louisiana (4)
Maine (11)
Maryland (206)
Massachusetts (765)
Michigan (37)
Minnesota (82)
Missouri (20)
Montana (6)
Nebraska (6)
Nevada (16)
New Hampshire (10)
New Jersey (407)
New Mexico (7)
New York (447)
North Carolina (173)
Northern California (495)
Ohio (36)
Oklahoma (4)
Oregon (5)
Pennsylvania (279)
Puerto Rico (3)
Rhode Island (4)
South America (381)
South Carolina (7)
Southern California (468)
Tennessee (16)
Texas (139)
Utah (19)
Virginia (23)
Washington D.C. (8)
Washington State (155)
Wisconsin (9)
178,391 Results for "boehringer mannheim group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Boehringer Ingelheim’s Lung Fibrosis Drug Scores Second Late-Stage Win
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary fibrosis—nearly six months after achieving a similar feat in idiopathic pulmonary fibrosis. Boehringer plans to submit for FDA and other global approvals in both indications.
February 10, 2025
·
2 min read
·
Heather McKenzie
Collaboration
Boehringer Ingelheim Expands Cancer Pipeline With Back-to-Back Antibody Deals
On Thursday, Boehringer Ingelheim announced a partnership with Synaffix to advance antibody-drug conjugates and exercised its fourth license option under a 2013 collaboration with Oxford BioTherapeutics.
January 10, 2025
·
2 min read
·
Tristan Manalac
Schizophrenia
Boehringer Suffers Phase III Schizophrenia Fail, Legal Parry by HHS
Boehringer Ingelheim’s trio of late-stage schizophrenia failures on Thursday came a day after the Department of Health and Human Services hit back on the pharma’s legal challenge to the IRA’s drug price negotiation program.
January 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Boehringer Ingelheim reaches more patients in 2024 and prepares new medicine launches
April 2, 2025
·
4 min read
Press Releases
Boehringer’s nerandomilast meets primary endpoint in Phase III study FIBRONEER™-ILD, in progressive pulmonary fibrosis
February 10, 2025
·
7 min read
Press Releases
Salipro Biotech and Boehringer Ingelheim Enter Research and License Agreement to Accelerate Multiple Boehringer Ingelheim Pipeline Programs
March 14, 2025
·
2 min read
Press Releases
Boehringer Ingelheim Partners with Veeva to Launch ‘One Medicine Platform’
March 11, 2025
·
3 min read
Press Releases
Boehringer Canada Announces Availability of SPEVIGO® for expanded indication in Canada
February 6, 2025
·
7 min read
Drug development
Boehringer, Insilico Appear to Break Through Against IPF
Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to stop progression, but the data were limited, leaving experts wanting.
September 24, 2024
·
4 min read
·
Heather McKenzie
Press Releases
Boehringer provides update on iclepertin Phase III program in schizophrenia
January 16, 2025
·
5 min read
1 of 17,840
Next
